S 1115

Making Pharmaceutical Markets More Competitive Act

Congress: 115 (2017–2019, Ended)
Chamber: Senate
Policy Area: Health
Introduced: May 11, 2017
Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (May 11, 2017)
Official Text: https://www.congress.gov/bill/115th-congress/senate-bill/1115

Sponsor

Name: Sen. Collins, Susan M. [R-ME]
Party: Republican • **State:** ME • **Chamber:** Senate

Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Cotton, Tom [R-AR]	R · AR		May 11, 2017
Sen. Franken, Al [D-MN]	D · MN		May 11, 2017
Sen. McCaskill, Claire [D-MO]	D · MO		May 11, 2017

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	May 11, 2017

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
115 HR 2562	Identical bill	**May 26, 2017:** Referred to the Subcommittee on Health.
115 S 934	Related bill	**May 11, 2017:** Placed on Senate Legislative Calendar under General Orders. Calendar No. 76.

Summary (as of May 11, 2017)

Making Pharmaceutical Markets More Competitive Act

This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to prioritize the review of generic drug applications and supplements with respect to drugs that are in a shortage or for which there are not more than three approved drugs.

The holder of an approved drug application must notify the FDA within 180 days of withdrawing or transferring the application or withdrawing the drug from sale.

The FDA must maintain a list of generic drugs with three or fewer holders of approved applications.

Actions Timeline

- **May 11, 2017:** Introduced in Senate
- **May 11, 2017:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.